July 2026– date –
-
Breakthroughs in iPSC and 3D Organoids Drive Stem Cell Therapies Towards Clinical Reality and Scalable Manufacturing
Academic/Industry Publication Unknown Overview Stem cell therapies are transitioning rapidly from promise to clinical reality, driven by recent advances in iPSC generation and differentiation. Innovative transcription factor mixes now en... -
Sonoma Biotherapeutics Automates Autologous CAR-Treg Therapy Manufacturing for Rheumatoid Arthritis with Cellares’ Cell Shuttle Platform
Regen Report USA Overview Sonoma Biotherapeutics partnered with Cellares to automate manufacturing of its Phase 1 autologous CAR-Treg therapy (SBT-77-7101) for treatment-resistant rheumatoid arthritis, using Cellares' Cell Shuttle platfo... -
FDA Clears Prime Medicine’s In Vivo Prime Editor for Wilson Disease, Setting Stage for 2027 Data
BioSpace USA Overview Prime Medicine has secured FDA Investigational New Drug (IND) clearance for PM577a, an in vivo Prime Editor designed to correct the H1069Q mutation in Wilson disease. This approval initiates a global Phase 1/2 clini... -
AI and Digital Twin Challenges in GMP Manufacturing: Regulators Demand Audit Trails for Continuously Learning Models
BioPharma APAC Singapore Overview AI and digital twin technologies promise breakthroughs in GMP biomanufacturing, enabling predictive maintenance, real-time release, and high yields. However, regulatory challenges concerning the validati... -
A4BEE Demonstrates Adaptive Digital Twin for Bioprocess Autonomy and Computer Vision for Non-Invasive Foam Management in Bioreactor Control
A4BEE Unknown Overview A4BEE has presented proof-of-concept for an adaptive digital twin aimed at bioprocess autonomy and computer vision for non-invasive foam management in bioreactor control. These innovations seek to bridge the gap be... -
CuraCell Pursues Gentler Preconditioning and Reduced Manufacturing Costs for CC-38 TIL Therapy for Solid Tumors, Enhancing Patient Eligibility and Cost-Effectiveness
Clinical Leader USA Overview CuraCell is focusing on a gentler preconditioning regimen and reduced manufacturing costs for its CC-38 T cell therapy program, which utilizes patient-derived tumor-infiltrating lymphocytes (TILs) for solid t... -
Eli Lilly Acquires Kelonia and Orna Therapeutics as Investment in In Vivo Cell Therapies Surges, Aiming to Reduce Treatment Burden and Manufacturing Costs
DCAT Value Chain Insights USA Overview In vivo cell therapies, where the patient's body becomes the manufacturing site for cells like CAR T cells, are attracting substantial biopharmaceutical investment due to their potential to reduce t... -
US Department of Energy’s ‘GENESIS MISSION’ Aims for Bioprocess Autonomy via AI and Digital Twins, Targeting Enhanced Yields and Cost Reduction
Department of Energy USA Overview The U.S. Department of Energy's 'GENESIS MISSION' seeks to connect biological design with manufacturing outcomes by integrating AI with experiments, structural analysis, models, biodiversity discovery, a... -
Scaling Animal-Free Proteins from Precision Fermentation Faces Challenges: Cost and Process Control Barriers from Lab to Market
MDPI Switzerland Overview Scaling animal-free proteins produced via precision fermentation from lab to industrial production faces significant challenges, including maintaining strain performance, high media costs, and precise bioprocess... -
Reinventing CAR T-Cell Access: How Localized Manufacturing in Turkey and China is Driving Down Costs
Bookimed Turkey Overview The prohibitively high cost of CAR T-cell therapy severely limits patient access worldwide, with prices fluctuating significantly based on manufacturing and treatment location. However, localized production, nota...
